Yersinia pseudotuberculosis infection Advocacy Hub | UniteRare

At a Glance

Live from database

No FDA or trial events recorded yet for Yersinia pseudotuberculosis infection.

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Yersinia pseudotuberculosis infection.
Check the disease page for updates →

1 FDA-approved

Priftin

(Rifapentine)Orphan drugstandard

Hoechst Marion Roussel

Rifamycin Antimycobacterial [EPC]

12.1 Mechanism of Action Rifapentine, a cyclopentyl rifamycin, is an antimycobacterial agent [see Microbiology (12.4) ] .

No active clinical trials currently recruiting for Yersinia pseudotuberculosis infection.
Search all trials →

No recent news articles indexed yet for Yersinia pseudotuberculosis infection.
Search PubMed for Yersinia pseudotuberculosis infection →

Top 1 by expertise

Siv Fonnes, MD

Centre for Perioperative Optimization, Department of Surgery, Herlev and Gentofte Hospitals, University of Copenhagen

View Disease Page

Full profile, treatments, community

Search Clinical Trials

Find recruiting studies now

Find Specialists

Ranked by expertise & trials

Financial Assistance

Copay cards, PAPs, grants